mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients

Molecular Oncology

Volumn 9, Issue 4, 2015, Pages 920-932

  Mostert, Bianca ^a   Sieuwerts, Anieta M ^a   Bolt de Vries, Joan ^a   Kraan, Jaco ^a   Lalmahomed, Zarina ^b   van Galen, Anne ^a   van der Spoel, Petra ^a   de Weerd, Vanja ^a   Ramírez Moreno, Raquel ^a   Smid, Marcel ^a   Verhoef, Cornelis ^b   IJzermans, Jan N M ^b   Gratama, Jan W ^a   Sleijfer, Stefan ^a   Foekens, John A ^a   Martens, John W M ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Circulating tumor cells; Gene expression; Liver resection; Metastatic colorectal cancer; Real time PCR

Indexed keywords

AGR2 PROTEIN; CDH17 PROTEIN; CYTOKERATIN; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 8; EPITHELIAL CELL ADHESION MOLECULE; FABP1 PROTEIN; IGFBP5 PROTEIN; KRT18 PROTEIN; KRT19 PROTEIN; KRT20 PROTEIN; KRT8 PROTEIN; MESSENGER RNA; PROTEIN; REG1A PROTEIN; TRANSCRIPTION FACTOR CDX1; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER PROGNOSIS; CANCER SURVIVAL; CELL COUNTING; CELL ISOLATION; CIRCULATING TUMOR CELL; CONTROLLED STUDY; FEMALE; GENE CLUSTER; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CELL COUNT; CLUSTER ANALYSIS; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TUMOR EMBOLISM;

BIOMARKERS, TUMOR; CELL COUNT; CLUSTER ANALYSIS; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; RNA, MESSENGER;

EID: 84926420089     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.01.001     Document Type: Article

References (60)

1. Abdalla E.K., Vauthey J.N., Ellis L.M., Ellis V., Pollock R., Broglio K.R., Hess K., Curley S.A. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann. Surg. 2004, 239:818-825. (discussion 825-817).
2. Adam R., de Haas R.J., Wicherts D.A., Aloia T.A., Delvart V., Azoulay D., Bismuth H., Castaing D. Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement?. J.Clin. Oncol. 2008, 26:3672-3680.
3. Alix-Panabieres C., Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin. Chem. 2013, 59:110-118.
4. Allan A.L., Keeney M. Circulating tumor cell analysis: technical and statistical considerations for application to the clinic. J.Oncol. 2010, 2010:426218.
5. Astrosini C., Roeefzaad C., Dai Y.Y., Dieckgraefe B.K., Jons T., Kemmner W. REG1A expression is a prognostic marker in colorectal cancer and associated with peritoneal carcinomatosis. Int. J. Cancer 2008, 123:409-413.
6. Attard G., Swennenhuis J.F., Olmos D., Reid A.H., Vickers E., A'Hern R., Levink R., Coumans F., Moreira J., Riisnaes R., Oommen N.B., Hawche G., Jameson C., Thompson E., Sipkema R., Carden C.P., Parker C., Dearnaley D., Kaye S.B., Cooper C.S., Molina A., Cox M.E., Terstappen L.W., de Bono J.S. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 2009, 69:2912-2918.
7. Ayez N., Lalmahomed Z.S., van der Pool A.E., Vergouwe Y., van Montfort K., de Jonge J., Eggermont A.M., Ijzermans J.N., Verhoef C. Is the clinical risk score for patients with colorectal liver metastases still useable in the era of effective neoadjuvant chemotherapy?. Ann. Surg. Oncol. 2011, 18:2757-2763.
8. Baldus S.E., Schaefer K.L., Engers R., Hartleb D., Stoecklein N.H., Gabbert H.E. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin. Cancer Res. 2010, 16:790-799.
9. Berndorff D., Gessner R., Kreft B., Schnoy N., Lajous-Petter A.M., Loch N., Reutter W., Hortsch M., Tauber R. Liver-intestine cadherin: molecular cloning and characterization of a novel Ca(2+)-dependent cell adhesion molecule expressed in liver and intestine. J.Cell Biol. 1994, 125:1353-1369.
10. Brouquet A., Abdalla E.K., Kopetz S., Garrett C.R., Overman M.J., Eng C., Andreou A., Loyer E.M., Madoff D.C., Curley S.A., Vauthey J.N. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J.Clin. Oncol. 2011, 29:1083-1090.
11. Campbell P.J., Yachida S., Mudie L.J., Stephens P.J., Pleasance E.D., Stebbings L.A., Morsberger L.A., Latimer C., McLaren S., Lin M.L., McBride D.J., Varela I., Nik-Zainal S.A., Leroy C., Jia M., Menzies A., Butler A.P., Teague J.W., Griffin C.A., Burton J., Swerdlow H., Quail M.A., Stratton M.R., Iacobuzio-Donahue C., Futreal P.A. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010, 467:1109-1113.
12. Cohen S.J., Alpaugh R.K., Gross S., O'Hara S.M., Smirnov D.A., Terstappen L.W., Allard W.J., Bilbee M., Cheng J.D., Hoffman J.P., Lewis N.L., Pellegrino A., Rogatko A., Sigurdson E., Wang H., Watson J.C., Weiner L.M., Meropol N.J. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin. Colorectal Cancer 2006, 6:125-132.
13. Cohen S.J., Punt C.J., Iannotti N., Saidman B.H., Sabbath K.D., Gabrail N.Y., Picus J., Morse M., Mitchell E., Miller M.C., Doyle G.V., Tissing H., Terstappen L.W., Meropol N.J. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J.Clin. Oncol. 2008, 26:3213-3221.
14. Coumans F.A., Doggen C.J., Attard G., de Bono J.S., Terstappen L.W. All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer. Ann. Oncol. 2010, 21:1851-1857.
15. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., Reuben J.M., Doyle G.V., Allard W.J., Terstappen L.W., Hayes D.F. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New Engl. J. Med. 2004, 351:781-791.
16. de Bono J.S., Scher H.I., Montgomery R.B., Parker C., Miller M.C., Tissing H., Doyle G.V., Terstappen L.W., Pienta K.J., Raghavan D. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 2008, 14:6302-6309.
17. Dennis G., Sherman B.T., Hosack D.A., Yang J., Gao W., Lane H.C., Lempicki R.A. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003, 4:P3.
18. Domon-Dell C., Schneider A., Moucadel V., Guerin E., Guenot D., Aguillon S., Duluc I., Martin E., Iovanna J., Launay J.F., Duclos B., Chenard M.P., Meyer C., Oudet P., Kedinger M., Gaub M.P., Freund J.N. Cdx1 homeobox gene during human colon cancer progression. Oncogene 2003, 22:7913-7921.
19. Eisen M.B., Spellman P.T., Brown P.O., Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:14863-14868.
20. Guo R.J., Suh E.R., Lynch J.P. The role of Cdx proteins in intestinal development and cancer. Cancer Biol. Ther. 2004, 3:593-601.
21. Holdhoff M., Schmidt K., Donehower R., Diaz L.A. Analysis of circulating tumor DNA to confirm somatic KRAS mutations. J.Natl. Cancer Inst. 2009, 101:1284-1285.
22. Huang da W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4:44-57.
23. Iinuma H., Watanabe T., Mimori K., Adachi M., Hayashi N., Tamura J., Matsuda K., Fukushima R., Okinaga K., Sasako M., Mori M. Clinical significance of circulating tumor cells, including Cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C Colorectal Cancer. J.Clin. Oncol. 2011, 29:1547-1555.
24. Imamura Y., Morikawa T., Liao X., Lochhead P., Kuchiba A., Yamauchi M., Qian Z.R., Nishihara R., Meyerhardt J.A., Haigis K.M., Fuchs C.S., Ogino S. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin. Cancer Res. 2012, 18:4753-4763.
25. Ito H., Are C., Gonen M., D'Angelica M., Dematteo R.P., Kemeny N.E., Fong Y., Blumgart L.H., Jarnagin W.R. Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer. Ann. Surg. 2008, 247:994-1002.
26. Jiang J., Mostert B., Lalmahomed Z., Ramírez-Moreno R., Sieuwerts A., Kraan J., IJzermans J., Verhoef C., Wang Y., Sleijfer S. KRAS and BRAF Mutation Status Analysis: Primary Tumor versus Metastasis and Circulating Tumor Cells in 42 Patients with Colorectal Cancer 2010, ASCO Molecular Markers (abstr 49).
27. Joosse S.A., Hannemann J., Spotter J., Bauche A., Andreas A., Muller V., Pantel K. Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells. Clin. Cancer Res. 2012, 18:993-1003.
28. Kim H., Nam S.W., Rhee H., Shan Li L., Ju Kang H., Hye Koh K., Kyu Kim N., Song J., Tak-Bun Liu E., Kim H. Different gene expression profiles between microsatellite instability-high and microsatellite stable colorectal carcinomas. Oncogene 2004, 23:6218-6225.
29. Koyanagi K., Bilchik A.J., Saha S., Turner R.R., Wiese D., McCarter M., Shen P., Deacon L., Elashoff D., Hoon D.S. Prognostic relevance of occult nodal micrometastases and circulating tumor cells in colorectal cancer in a prospective multicenter trial. Clin. Cancer Res. 2008, 14:7391-7396.
30. Lalmahomed Z.S., Kraan J., Gratama J.W., Mostert B., Sleijfer S., Verhoef C. Circulating tumor cells and sample size: the more, the better. J.Clin. Oncol. 2010, 28:e288-e289. (author reply e290).
31. Lawrie L.C., Dundas S.R., Curran S., Murray G.I. Liver fatty acid binding protein expression in colorectal neoplasia. Br. J. Cancer 2004, 90:1955-1960.
32. Lee W.S., Seo G., Shin H.J., Yun S.H., Yun H., Choi N., Lee J., Son D., Cho J., Kim J., Cho Y.B., Chun H.K., Lee W.Y. Identification of differentially expressed genes in microsatellite stable HNPCC and sporadic colon cancer. J.Surg. Res. 2008, 144:29-35.
33. Lochhead P., Imamura Y., Morikawa T., Kuchiba A., Yamauchi M., Liao X., Qian Z.R., Nishihara R., Wu K., Meyerhardt J.A., Fuchs C.S., Ogino S. Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. Eur. J. Cancer 2012, 48:3405-3413.
34. Lochhead P., Kuchiba A., Imamura Y., Liao X., Yamauchi M., Nishihara R., Qian Z.R., Morikawa T., Shen J., Meyerhardt J.A., Fuchs C.S., Ogino S. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J.Natl. Cancer Inst. 2013, 105:1151-1156.
35. Lynch J., Keller M., Guo R.J., Yang D., Traber P. Cdx1 inhibits the proliferation of human colon cancer cells by reducing cyclin D1 gene expression. Oncogene 2003, 22:6395-6407.
36. Moll R., Lowe A., Laufer J., Franke W.W. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am. J. Pathol. 1992, 140:427-447.
37. Mori Y., Yin J., Sato F., Sterian A., Simms L.A., Selaru F.M., Schulmann K., Xu Y., Olaru A., Wang S., Deacu E., Abraham J.M., Young J., Leggett B.A., Meltzer S.J. Identification of genes uniquely involved in frequent microsatellite instability colon carcinogenesis by expression profiling combined with epigenetic scanning. Cancer Res. 2004, 64:2434-2438.
38. Mostert B., Kraan J., Bolt-de Vries J., van der Spoel P., Sieuwerts A.M., Schutte M., Timmermans A.M., Foekens R., Martens J.W., Gratama J.W., Foekens J.A., Sleijfer S. Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. Breast Cancer Res. Treat. 2011, 127:33-41.
39. Mostert B., Kraan J., Sieuwerts A.M., van der Spoel P., Bolt-de Vries J., Prager-van der Smissen W.J.C., Smid M., Timmermans A.M., Martens J.W.M., Gratama J.W., Foekens J.A., Sleijfer S. CD49f-based selection of circulating tumor cells (CTCs) improves detection across breast cancer subtypes. Cancer Lett. 2012, 319(1):49-55.
40. Mouradov D., Domingo E., Gibbs P., Jorissen R.N., Li S., Soo P.Y., Lipton L., Desai J., Danielsen H.E., Oukrif D., Novelli M., Yau C., Holmes C.C., Jones I.T., McLaughlin S., Molloy P., Hawkins N.J., Ward R., Midgely R., Kerr D., Tomlinson I.P., Sieber O.M. Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. Am. J. Gastroenterol. 2013, 108:1785-1793.
41. Phipps A.I., Buchanan D.D., Makar K.W., Win A.K., Baron J.A., Lindor N.M., Potter J.D., Newcomb P.A. KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. Br. J. Cancer 2013, 108:1757-1764.
42. Riethdorf S., Muller V., Zhang L., Rau T., Loibl S., Komor M., Roller M., Huober J., Fehm T., Schrader I., Hilfrich J., Holms F., Tesch H., Eidtmann H., Untch M., von Minckwitz G., Pantel K. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin. Cancer Res. 2010, 16:2634-2645.
43. Russo A.L., Borger D.R., Szymonifka J., Ryan D.P., Wo J.Y., Blaszkowsky L.S., Kwak E.L., Allen J.N., Wadlow R.C., Zhu A.X., Murphy J.E., Faris J.E., Dias-Santagata D., Haigis K.M., Ellisen L.W., Iafrate A.J., Hong T.S. Mutational analysis and clinical correlation of metastatic colorectal cancer. Cancer 2014, 120:1482-1490.
44. Sanz-Pamplona R., Berenguer A., Cordero D., Riccadonna S., Sole X., Crous-Bou M., Guino E., Sanjuan X., Biondo S., Soriano A., Jurman G., Capella G., Furlanello C., Moreno V. Clinical value of prognosis gene expression signatures in colorectal cancer: a systematic review. PLoS One 2012, 7:e48877.
45. Sieuwerts A.M., Kraan J., Bolt-de Vries J., van der Spoel P., Mostert B., Martens J.W., Gratama J.W., Sleijfer S., Foekens J.A. Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Res. Treat. 2009, 118:455-468.
46. Sieuwerts A.M., Kraan J., Bolt-de Vries J., van der Spoel P., Mostert B., Martens J.W.M., Gratama J.W., Sleijfer S., Foekens J.A. Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Res. Treat. 2009, 118:455-468.
47. Sieuwerts A.M., Mostert B., Bolt-de Vries J., Peeters D., de Jongh F.E., Stouthard J.M., Dirix L.Y., van Dam P.A., Van Galen A., de Weerd V., Kraan J., van der Spoel P., Ramirez-Moreno R., van Deurzen C.H., Smid M., Yu J.X., Jiang J., Wang Y., Gratama J.W., Sleijfer S., Foekens J.A., Martens J.W. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast Cancer patients. Clin. Cancer Res. 2011, 17:3600-3618.
48. Smirnov D.A., Zweitzig D.R., Foulk B.W., Miller M.C., Doyle G.V., Pienta K.J., Meropol N.J., Weiner L.M., Cohen S.J., Moreno J.G., Connelly M.C., Terstappen L.W., O'Hara S.M. Global gene expression profiling of circulating tumor cells. Cancer Res. 2005, 65:4993-4997.
49. Su M.C., Yuan R.H., Lin C.Y., Jeng Y.M. Cadherin-17 is a useful diagnostic marker for adenocarcinomas of the digestive system. Mod. Pathol. 2008, 21:1379-1386.
50. Taylor I. Liver metastases from colorectal cancer: lessons from past and present clinical studies. Br. J. Surg. 1996, 83:456-460.
51. Terrin L., Rampazzo E., Pucciarelli S., Agostini M., Bertorelle R., Esposito G., DelBianco P., Nitti D., De Rossi A. Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implications for monitoring of neoplastic disease. Clin. Cancer Res. 2008, 14:7444-7451.
52. van de Stolpe A., Pantel K., Sleijfer S., Terstappen L.W., den Toonder J.M. Circulating tumor cell isolation and diagnostics: toward routine clinical use. Cancer Res. 2011, 71:5955-5960.
53. van der Pool A.E., de Wilt J.H., Lalmahomed Z.S., Eggermont A.M., Ijzermans J.N., Verhoef C. Optimizing the outcome of surgery in patients with rectal cancer and synchronous liver metastases. Br. J. Surg. 2010, 97:383-390.
54. Verhoef C., van der Pool A.E., Nuyttens J.J., Planting A.S., Eggermont A.M., de Wilt J.H. The "liver-first approach" for patients with locally advanced rectal cancer and synchronous liver metastases. Dis. Colon Rectum 2009, 52:23-30.
55. Vlems F.A., Diepstra J.H.S., Punt C.J.A., Ligtenberg M.J.L., Cornelissen I.M.H.A., van Krieken J.H.J.M., Wobbes T., van Muijen G.N.P., Ruers T.J.M. Detection of disseminated tumour cells in blood and bone marrow samples of patients undergoing hepatic resection for metastasis of colorectal cancer. Br. J. Surg. 2003, 90:989-995.
56. Wang Y., Jatkoe T., Zhang Y., Mutch M.G., Talantov D., Jiang J., McLeod H.L., Atkins D. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J.Clin. Oncol. 2004, 22:1564-1571.
57. Xi L., Nicastri D.G., El-Hefnawy T., Hughes S.J., Luketich J.D., Godfrey T.E. Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers. Clin. Chem. 2007, 53:1206-1215.
58. Yamazaki T., Kanda T., Sakai Y., Hatakeyama K. Liver fatty acid-binding protein is a new prognostic factor for hepatic resection of colorectal cancer metastases. J.Surg. Oncol. 1999, 72:83-87.
59. Yie S.M., Lou B., Ye S.R., Cao M., He X., Li P., Hu K., Rao L., Wu S.M., Xiao H.B., Gao E. Detection of survivin-expressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse. Ann. Surg. Oncol. 2008, 15:3073-3082.
60. Zakaria S., Donohue J.H., Que F.G., Farnell M.B., Schleck C.D., Ilstrup D.M., Nagorney D.M. Hepatic resection for colorectal metastases: value for risk scoring systems?. Ann. Surg. 2007, 246:183-191.